Search

Protagonist Therapeutics Inc

Затворен

СекторЗдравеопазване

142.84 -0.09

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

140.51

Максимум

144.3

Ключови измерители

By Trading Economics

Приходи

159M

163M

Продажби

157M

213M

P/E

Средно за сектора

143.476

56.432

EPS

2.29

Марж на печалбата

76.285

Служители

141

EBITDA

162M

165M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+16.21% upside

Дивиденти

By Acuity

Следващи печалби

4.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.1B

9.6B

Предишно отваряне

142.93

Предишно затваряне

142.84

Настроения в новините

By Acuity

27%

73%

38 / 339 Класиране в Healthcare

Protagonist Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.09.2026 г., 20:06 ч. UTC

Protagonist Therapeutics Inc shares fell sharply, remaining below their 20-day moving average and near the lower end of their one-month range.

17.09.2026 г., 19:46 ч. UTC

Protagonist Therapeutics Inc shares are trading roughly flat, currently below their opening level and the 20-day moving average after three consecutive lower closes.

16.09.2026 г., 19:13 ч. UTC

Protagonist Therapeutics Inc shares fell sharply amid a broader market decline, influenced by mixed economic data and cautious investor sentiment ahead of jobless claims.

15.09.2026 г., 20:07 ч. UTC

Protagonist Therapeutics shares are lower amid broader market concerns, following a significant drop in the NY Empire State Manufacturing Index for September.

11.09.2026 г., 20:08 ч. UTC

News

Protagonist Therapeutics shares are higher as CEO Dinesh V. Patel exercises options and sells over 70,000 shares, boosting investor sentiment.

9.09.2026 г., 20:07 ч. UTC

News
Social Media

Protagonist Therapeutics announced a $300 million share repurchase program, but shares are trading lower during Wednesday's session after pulling back from an earlier high.

2.09.2026 г., 20:08 ч. UTC

Social Media

Protagonist Therapeutics shares are lower despite Barclays setting a $180 price target following the approval of Mimrylo for polycythemia vera treatment.

1.09.2026 г., 19:36 ч. UTC

News
Social Media

Protagonist Therapeutics shares are lower today, despite analysts raising price targets following the approval of Mimrylo. Barclays set a target of $180.

28.08.2026 г., 20:02 ч. UTC

Protagonist Therapeutics Inc is declining during Friday's session, reversing earlier gains amid rising U.S. Treasury yields and broader market dynamics.

27.08.2026 г., 20:07 ч. UTC

Protagonist Therapeutics Inc shares are lower during Thursday's session, continuing a decline since Wednesday amid broader market conditions and economic resilience signals.

26.08.2026 г., 20:08 ч. UTC

Protagonist Therapeutics Inc shares are trading higher today. No specific news was identified to explain the movement amid mixed broader market conditions.

25.08.2026 г., 23:36 ч. UTC

Protagonist Therapeutics Inc. sees modest gains in after-market trading amid a broader market backdrop of declining crude oil prices and easing geopolitical tensions.

24.08.2026 г., 20:06 ч. UTC

Protagonist Therapeutics shares are higher today, recovering from an earlier dip. The broader market also shows slight gains since Friday's close.

21.08.2026 г., 20:06 ч. UTC

Protagonist Therapeutics Inc is rising during Friday's session, showing steady gains since Thursday amid a broader market boost from Bitcoin's surge.

20.08.2026 г., 19:31 ч. UTC

Correlated Moves

Protagonist Therapeutics Inc shares are lower today amid a decline in the Biotechnology sector, with unusually high trading volume noted during the session.

19.08.2026 г., 19:46 ч. UTC

Protagonist Therapeutics Inc shares are lower today, retracing from earlier highs. The price remains above its 20-day moving average amid no specific news.

17.08.2026 г., 19:46 ч. UTC

Social Media
News

BMO Capital raised Protagonist Therapeutics' price target to $178, maintaining an Outperform rating, as shares trade higher amid positive pipeline developments.

14.08.2026 г., 22:36 ч. UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

13.08.2026 г., 20:06 ч. UTC

Correlated Moves
News
Social Media

Protagonist Therapeutics shares are lower amid insider selling concerns following CEO Dinesh V. Patel's recent stock transactions. The decline reflects broader sector trends.

12.08.2026 г., 23:31 ч. UTC

Social Media

Protagonist Therapeutics Inc gains after-market, reaching a high above Wednesday's close. Investor interest grows amid social media discussions on increasing positions.

11.08.2026 г., 23:01 ч. UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement amid earlier volatility and fluctuations.

10.08.2026 г., 23:46 ч. UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, with notable strength above the 20-day moving average and near the upper end of its one-month range.

6.08.2026 г., 19:52 ч. UTC

Social Media
News

Protagonist Therapeutics shares rise following multiple price target upgrades, including Citi's increase to $175, amid positive sentiment on drug approvals and pharmacokinetic data.

5.08.2026 г., 22:02 ч. UTC

News

Protagonist Therapeutics reports Q2 net income of $162.8 million, up from a loss last year. Shares are higher in after-market trading following the results.

4.08.2026 г., 21:03 ч. UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, supported by their position above the 20-day moving average. No specific news was identified.

3.08.2026 г., 19:36 ч. UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

31.07.2026 г., 19:36 ч. UTC

Correlated Moves

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

30.07.2026 г., 21:02 ч. UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

29.07.2026 г., 19:43 ч. UTC

Macro Event

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

28.07.2026 г., 21:01 ч. UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

Сравнение с други в отрасъла

Ценова промяна

Protagonist Therapeutics Inc Прогноза

Ценова цел

By TipRanks

16.21% нагоре

12-месечна прогноза

Среден 167 USD  16.21%

Висок 186 USD

Нисък 121 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Protagonist Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

12

Купи

0

Задържане

0

Продай

Настроение

By Acuity

38 / 339 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.